ResApp Health's share price has been on a rollercoaster ride, the broker notes, from the disappointing FDA setback to virus-inspired awareness of the company's telehealth applications, which are enjoying a sustained increase in demand.
The broker has made no change to forecasts at this stage. Add and 24c target retained, with upside risk offered by ResApp's new obstructive sleep apnea product.
Sector: Health Care Equipment & Services.
Target price is $0.24.Current Price is $0.19. Difference: $0.05 - (brackets indicate current price is over target). If RAP meets the Morgans target it will return approximately 21% (excluding dividends, fees and charges - negative figures indicate an expected loss).
© 2020 Acquisdata Pty Ltd., source FN Arena